Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for controlling rare immune disorder

NCT ID NCT05063110

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

35 people

The number who actually took part.

Started

May 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients age \> 18 years, * Patient is willing to provide written informed consent prior to enrolment and agrees to follow the protocol * Patient known to have systemic juvenile idiopathic arthritis are classified as having HLH * Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception for the duration of the study * Be either affiliated to, or a beneficiary of, a social security category Exclusion Criteria: * Organ failure: confusion, organic kidney failure KDIGO 2 criteria, liver failure (Factor V \< 50%), heart failure, respiratory failure. * Fibrinogen \< 0.50 g/l, platelets \<20G/L * Indication to intensive care unit transfer on an organ failure requiring assistance (dialysis, Ventilation (assisted or VNI), shock regardless of the origin. * Breastfeeding women * Patient participating in another investigational therapeutic study * Women with a positive pregnancy test or not willing to take contraceptive measures * Known allergies, hypersensitivity, or intolerance to any of the ITACITINIB or excipients, or similar compounds * Current or history of recurrent infections, including HBV, HCV * Participants with active HBV or HCV infection that requires treatment or who are at risk for HBV reactivation (ie Positive HBs Ag serology) * Candidates positive for HCV antibody and positive PCR RNA HCV * HIV infection with positive viral charge * Protected adults (including individual under guardianship by court order) * Vulnerable adults, under a safeguard of justice measure * Adults deprived of their liberty by judicial or administrative decision * Persons under psychiatric care without their consent * Persons admitted to social institution for purposes other this research * Adults under legal protection (guardianship or curatorship) * Persons unable to express their consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adults patients having non severe HLH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Avicenne

    Bobigny, Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.